Tempus AI (NASDAQ:TEM) Sets New 1-Year High – Should You Buy?

Shares of Tempus AI, Inc. (NASDAQ:TEM) hit a new 52-week high during trading on Thursday . The stock traded as high as $80.70 and last traded at $80.24, with a volume of 7026374 shares. The stock had previously closed at $73.88.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. TD Cowen reiterated a “buy” rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital dropped their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Guggenheim began coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price target for the company. Finally, Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.55.

Tempus AI Stock Up 14.9 %

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm’s 50 day simple moving average is $45.21 and its two-hundred day simple moving average is $49.73.

Insider Activity at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrew Polovin sold 51,504 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the sale, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,229,449 shares of company stock worth $102,293,124.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TEM. Kovitz Investment Group Partners LLC bought a new stake in shares of Tempus AI during the third quarter worth about $1,367,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Tempus AI in the fourth quarter valued at approximately $1,091,000. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors bought a new stake in Tempus AI during the third quarter worth $2,726,000. Finally, Sigma Planning Corp bought a new stake in Tempus AI during the third quarter worth $1,323,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.